We serve Chemical Name:6-Bromo-7-fluoroquinoline CAS:127827-52-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Bromo-7-fluoroquinoline
CAS.NO:127827-52-5
Synonyms:6-Bromo-7-fluoroquinoline;Quinoline, 6-bromo-7-fluoro-
Molecular Formula:C9H5BrFN
Molecular Weight:226.045
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:295.7±20.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.647
PSA:12.89000
Exact Mass:224.958939
LogP:2.92
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-Bromo-7-fluoroquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Quinoline, 6-bromo-7-fluoro- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Quinoline, 6-bromo-7-fluoro- Use and application,6-Bromo-7-fluoroquinoline technical grade,usp/ep/jp grade.
Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2-(N-(carbamoylmethyl)-4-methylbenzenesulfonimido)-6-(phenylthio)pyridine manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 6-(4-methoxy-phenyl)-3-naphthalen-1-yl-4-phenyl-pyran-2-one suppliers Expedite biocatalysis development by partnering with an API CDMO trans-(1S,2S)-Bis(2-{[N-Boc-(S)-prolyl]amino}phenyl)cyclopentane vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2-(N-(carbamoylmethyl)-4-methylbenzenesulfonimido)-6-(phenylthio)pyridine manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 6-(4-methoxy-phenyl)-3-naphthalen-1-yl-4-phenyl-pyran-2-one suppliers Expedite biocatalysis development by partnering with an API CDMO trans-(1S,2S)-Bis(2-{[N-Boc-(S)-prolyl]amino}phenyl)cyclopentane vendor & factory.
